124 |
Bartlett A.W., Sudjaritruk T., Mohamed T.J., Anugulruengkit S., Kumarasamy N., Phongsamart W., Ly P.S., Truong K.H., Van Nguyen L., Do V.C., Ounchanum P., Puthanakit T., Chokephaibulkit K., Lumbiganon P., Kurniati N., Nik Yusoff N.K., Wati D.K., Sohn A.H., Kariminia A. |
56511395900;36538198800;46961185600;57209773680;7003549856;8885235300;9743902800;35811540200;54396225800;56732729400;57200558813;8071686900;7003974471;35564244800;36473260300;6504631866;55816676300;7006405275;6602745222; |
Identification, Management, and Outcomes of Combination Antiretroviral Treatment Failure in Adolescents With Perinatal Human Immunodeficiency Virus Infection in Asia |
2021 |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
73 |
7 |
|
e1919 |
e1926 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118283335&doi=10.1093%2fcid%2fciaa872&partnerID=40&md5=7af8cf47bd95718a30d3277b5797f9ba |
Kirby Institute, University of New South Wales, Sydney, Australia; Department of Pediatrics, Faculty of Medicine, Research Institute for Health Sciences, Chiang Mai UniversityChiang Mai, Thailand; Women and Children Hospital Kuala LumpurKuala Lumpur, Malaysia; Department of Pediatrics, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Chennai Antiviral Research and Treatment Clinical Research Site, VHS-Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India; Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, Thailand; National Centre for HIV/AIDS, Dermatology and Sexually Transmitted DiseasesPhnom Penh, Cambodia; Children's Hospital 1, Ho Chi Minh City, Viet Nam; National Hospital of PediatricsHanoi, Viet Nam; Children's Hospital 2, Ho Chi Minh City, Viet Nam; Chiangrai Prachanukroh HospitalChiang Rai, Thailand; Department of Pediatrics, Faculty of Medicine, Khon Kaen UniversityKhon Kaen, Thailand; Cipto Mangunkusumo-Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Hospital Raja Perempuan Zainab IIKelantan, Malaysia; Sanglah Hospital, Udayana UniversityBali, Indonesia; TREAT Asia, amfAR-the Foundation for AIDS ResearchBangkok, Thailand |
Bartlett, A.W., Kirby Institute, University of New South Wales, Sydney, Australia; Sudjaritruk, T., Department of Pediatrics, Faculty of Medicine, Research Institute for Health Sciences, Chiang Mai UniversityChiang Mai, Thailand; Mohamed, T.J., Women and Children Hospital Kuala LumpurKuala Lumpur, Malaysia; Anugulruengkit, S., Department of Pediatrics, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand, Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Kumarasamy, N., Chennai Antiviral Research and Treatment Clinical Research Site, VHS-Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India; Phongsamart, W., Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, Thailand; Ly, P.S., National Centre for HIV/AIDS, Dermatology and Sexually Transmitted DiseasesPhnom Penh, Cambodia; Truong, K.H., Children's Hospital 1, Ho Chi Minh City, Viet Nam; Van Nguyen, L., National Hospital of PediatricsHanoi, Viet Nam; Do, V.C., Children's Hospital 2, Ho Chi Minh City, Viet Nam; Ounchanum, P., Chiangrai Prachanukroh HospitalChiang Rai, Thailand; Puthanakit, T., Department of Pediatrics, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand, Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn UniversityBangkok, Thailand; Chokephaibulkit, K., Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol UniversityBangkok, Thailand; Lumbiganon, P., Department of Pediatrics, Faculty of Medicine, Khon Kaen UniversityKhon Kaen, Thailand; Kurniati, N., Cipto Mangunkusumo-Faculty of Medicine Universitas IndonesiaJakarta, Indonesia; Nik Yusoff, N.K., Hospital Raja Perempuan Zainab IIKelantan, Malaysia; Wati, D.K., Sanglah Hospital, Udayana UniversityBali, Indonesia; Sohn, A.H., TREAT Asia, amfAR-the Foundation for AIDS ResearchBangkok, Thailand; Kariminia, A., Kirby Institute, University of New South Wales, Sydney, Australia |
BACKGROUND: Combination antiretroviral therapy (cART) failure is a major threat to human immunodeficiency virus (HIV) programs, with implications for individual- and population-level outcomes. Adolescents with perinatally acquired HIV infection (PHIVA) should be a focus for treatment failure given their poorer outcomes compared to children and adults. METHODS: Data (2014-2018) from a regional cohort of Asian PHIVA who received at least 6 months of continuous cART were analyzed. Treatment failure was defined according to World Health Organization criteria. Descriptive analyses were used to report treatment failure and subsequent management and evaluate postfailure CD4 count and viral load trends. Kaplan-Meier survival analyses were used to compare the cumulative incidence of death and loss to follow-up (LTFU) by treatment failure status. RESULTS: A total 3196 PHIVA were included in the analysis with a median follow-up period of 3.0 years, of whom 230 (7.2%) had experienced 292 treatment failure events (161 virologic, 128 immunologic, 11 clinical) at a rate of 3.78 per 100 person-years. Of the 292 treatment failure events, 31 (10.6%) had a subsequent cART switch within 6 months, which resulted in better immunologic and virologic outcomes compared to those who did not switch cART. The 5-year cumulative incidence of death and LTFU following treatment failure was 18.5% compared to 10.1% without treatment failure. CONCLUSIONS: Improved implementation of virologic monitoring is required to realize the benefits of virologic determination of cART failure. There is a need to address issues related to accessibility to subsequent cART regimens, poor adherence limiting scope to switch regimens, and the role of antiretroviral resistance testing. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. |
adolescent; antiretroviral therapy; HIV; treatment failure |
anti human immunodeficiency virus agent; adolescent; adult; Asia; CD4 lymphocyte count; child; female; human; Human immunodeficiency virus infection; pregnancy; treatment failure; virus load; Adolescent; Adult; Anti-HIV Agents; Asia; CD4 Lymphocyte Count; Child; Female; HIV Infections; Humans; Pregnancy; Treatment Failure; Viral Load |
NLM (Medline) |
15376591 |
|
32589711 |
Article |
Q1 |
3440 |
518 |
|
|
173 |
Forrat R., Dayan G.H., DiazGranados C.A., Bonaparte M., Laot T., Capeding M.R., Sanchez L., Coronel D.L., Reynales H., Chansinghakul D., Hadinegoro S.R.S., Perroud A.P., Frago C., Zambrano B., Machabert T., Wu Y., Luedtke A., Price B., Vigne C., Haney O., Savarino S.J., Bouckenooghe A., Noriega F. |
36339272700;6701860993;56721307400;56614799700;24471016000;6602161242;57201082261;56418742600;55343075300;29067671300;56893685800;57198777256;56255310300;7801355579;57201364463;57215829074;54395741500;57002517700;57192890936;57215866119;57220410062;18233281300;7005980306; |
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America |
2021 |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
73 |
6 |
|
1003 |
1012 |
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116958578&doi=10.1093%2fcid%2fciab288&partnerID=40&md5=cceec1a946e6b236b138dcb4bb663855 |
Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Clinical Sciences Sanofi PasteurPA, United States; Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Research Institute for Tropical Medicine, Medical Department, Muntinlupa, Philippines; Clinical Sciences, Sanofi PasteurMexico City, Mexico; Centro de Atencion e Investigación Médica, Bogotá, Colombia; Research & Development, Sanofi PasteurBangkok, Thailand; Cipto Mangunkusumo Hospital, University of IndonesiaJakarta, Indonesia; Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Clinical Sciences, Sanofi Pasteur, Singapore; Clinical Sciences, Sanofi Pasteur, Uruguay; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Global Pharmacovigilance, Sanofi PasteurPA, United States |
Forrat, R., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Dayan, G.H., Clinical Sciences Sanofi PasteurPA, United States; DiazGranados, C.A., Clinical Sciences Sanofi PasteurPA, United States; Bonaparte, M., Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Laot, T., Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Capeding, M.R., Research Institute for Tropical Medicine, Medical Department, Muntinlupa, Philippines; Sanchez, L., Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines; Coronel, D.L., Clinical Sciences, Sanofi PasteurMexico City, Mexico; Reynales, H., Centro de Atencion e Investigación Médica, Bogotá, Colombia; Chansinghakul, D., Research & Development, Sanofi PasteurBangkok, Thailand; Hadinegoro, S.R.S., Cipto Mangunkusumo Hospital, University of IndonesiaJakarta, Indonesia; Perroud, A.P., Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Frago, C., Clinical Sciences, Sanofi Pasteur, Singapore; Zambrano, B., Clinical Sciences, Sanofi Pasteur, Uruguay; Machabert, T., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Wu, Y., Clinical Sciences Sanofi PasteurPA, United States; Luedtke, A., Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Price, B., Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; Vigne, C., Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France; Haney, O., Global Pharmacovigilance, Sanofi PasteurPA, United States; Savarino, S.J., Translation Sciences and Biomarkers, Sanofi PasteurPA, United States; Bouckenooghe, A., Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil; Noriega, F., Clinical Sciences Sanofi PasteurPA, United States |
BACKGROUND: CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved for the prevention of symptomatic dengue in previously dengue exposed individuals. This post hoc analysis assessed hospitalized and severe virologically confirmed dengue (VCD) over the complete 6-year follow-up of 3 CYD-TDV efficacy studies (CYD14, CYD15, and CYD23/CYD57). METHODS: The main outcomes were hazard ratios (HRs) for hospitalized or severe VCD by baseline dengue serostatus, focusing on those who were seropositive, and by age at immunization (<9 years/≥9 years). Baseline dengue serostatus was measured or inferred using several methods. Hospitalized VCD cases were characterized in terms of clinical signs and symptoms and wild-type viremia level. Antibody persistence was assessed up to 5 years after the last injection. RESULTS: In those aged ≥9 years and baseline seropositive, CYD-TDV protected against hospitalized and severe VCD over 6 years compared to placebo (HR [95% confidence interval] multiple imputation from month 0 method, .19 [.12-.30] and .15 [.06-.39]; other methods were consistent). Vaccine protection was observed over the different study periods, being highest during the first 2 years. Evidence for a decreased risk of hospitalized and severe VCD was also observed in seropositive participants aged 6-8 years. Clinical signs and symptoms, and quantified dengue viremia from participants with hospitalized VCD were comparable between groups. CONCLUSIONS: CYD-TDV demonstrated robust protection against hospitalized and severe VCD over the entire 6-year follow-up in participants who were seropositive and ≥9 years old. Protection was also observed in seropositive 6-8 year-olds. Clinical Trials Registration: NCT00842530, NCT01983553, NCT01373281, NCT01374516. © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. |
CYD-TDV; dengue; serostatus; VCD |
dengue vaccine; live vaccine; vaccine; virus antibody; Asia; child; controlled study; dengue; Dengue virus; follow up; human; randomized controlled trial; severe dengue; South and Central America; Antibodies, Viral; Asia; Child; Dengue; Dengue Vaccines; Dengue Virus; Follow-Up Studies; Humans; Latin America; Severe Dengue; Vaccines, Attenuated; Vaccines, Combined |
NLM (Medline) |
15376591 |
|
33822015 |
Article |
Q1 |
3440 |
518 |
|
|